

CURRICULUM VITAE

INFORMATIONS PERSONNELLES

Nom **MUELLER, JUDITH E.**
Adresse EHESP site parisien
20 avenue George Sand
93210 La Plaine St Denis
Téléphone +33-(0)2.99.02.24.32
Courrier électronique judith.mueller@ehesp.fr
Langues parlées, lues, écrites : allemand, anglais, français

EXPERIENCE PROFESSIONNELLE

Depuis 2011
ECOLE DES HAUTES ETUDES EN SANTE PUBLIQUE (EHESP), Rennes
- Professeur en épidémiologie, Département de Méthodes quantitatives en santé publique
- Rattachement pour la recherche à l'INSTITUT PASTEUR, Unité de l'Epidémiologie des Maladies Emergentes
- Directrice adjointe du Réseau doctoral en santé publique

2002 - 2011
AGENCE DE MEDECINE PREVENTIVE (AMP), Paris
Médecin épidémiologiste, Responsable du Programme de Recherche sur les Méningites et Pneumonies

2000 – 2002
GSF NATIONAL RESEARCH CENTER, Oberschleissheim / Allemagne
Médecin épidémiologiste

1997 – 1998
CHU KLINIKUM RECHTS DER ISAR, Munich / Allemagne
Médecin (Arzt im Praktikum) en gynécologie et obstétrique

EDUCATION ET FORMATION

2012
Université de Pierre et Marie Curie (Paris 6), Paris
HABILITATION A DIRIGER DES RECHERCHES

2004 - 2008
Université de Pierre et Marie Curie (Paris 6), Ecole Doctorale-393, Paris
Epidémiologie / Santé publique et Sciences de l'information biomédicale
DIPLOME DE DOCTEUR

1999 - 2000
Harvard School of Public Health, Boston, USA
Public Health, Concentration : Méthodes quantitatives
MASTER OF PUBLIC HEALTH

1990 -1997, 2000
Technische Universität München, Munich, Allemagne
Médecine
EXAMEN D'ÉTAT (MD), DIPLOME DE DOCTEUR EN MEDECINE (DR. MED.)

PROJETS EN COURS

Identification, co-construction et évaluation d'une intervention multi-composantes visant à améliorer l'acceptabilité de la vaccination contre le PapillomaVirus Humain (HPV) en France (PrevHPV)

Coordinateur de l'équipe 7, partenaires : J. Raude (EHESP), J. Sicsic (Université de Paris), I. Bonmarin et A-S. Barret (Santé Publique France).

- Evaluation des préférences des adolescents et leurs parents par des études de choix discrets (single profile) ;
- Evaluation de l'effet des interventions sur les connaissances, attitudes pratiques relatif au vaccin HPV ;

Financement : IReSP

Période : 2019-2022

Partenaires : Consortium PrevHPV sous la coordination de Nathalie Thilly, Université de Lorraine.

PrefMeCo - Enquête sur les préférences autour des mesures de contrôle de l'épidémie à SARS Cov2

Financement : aucun

Période : 2020-21

Partenaires : J. Sicsic (Université de Paris)

Financement : aucun

Enquête GERES : Covid-19, quelle(s) vaccination(s) ?

Pratique et intention de vaccinations contre la grippe saisonnière et la Covid-19 chez les soignants français.

Période : 2020-21

Partenaires : GERES, HAS

Projet de thèse Frédérique Dorleans, Santé publique France

Acceptabilité, déterminants et préférences de la vaccination contre les infections à HPV aux Antilles françaises en vue d'en améliorer l'adhésion

Période : 2020-2023

PhD project Kimberly Bonner, University of Minnesota

Makerere University Students Vaccination Preferences Study (Uganda)

Exploring preferences in willingness to receive an influenza vaccine: a discrete choice experiment in three age groups of Minnesota residents (USA)

Financement : Fogarty Scholarship

Période : 2018-2020

Partenaires : J. Sicsic (Université de Paris), N. Basta (University McGill, supervisor)

Amélioration de la protection de la population nigérienne face au risque d'épidémie de méningite (PROPOMEN)

Financement : DCI Monaco

Période : 2018-2020 (prolongation prévue)

Partenaires: Institut Pasteur Paris et CERMES/ Niger (promoteur)

ConjointVac Students

Etudes comparatives France, Allemagne, Ecosse

Partenaires: C. Holmberg (Medizinische Hochschule Brandenburg Theodor Fontane), U. Schlipkötter (LMU München/Allemagne), L. Willocks (University of Edinburgh/UK), J. Raude (EHESP), J. Sicsic (Université Descartes)

ConjointVac Soignants

Financement: PRINCEPS (USPC)

Période : 2018

Partenaires: J. Raude (EHESP), J. Sicsic (Université Descartes), E. Bouvet et al. (GERES)

SELECTION DE PUBLICATIONS

1. Escolano S, **Mueller JE**, Tuber-Bitter P. Accounting for indirect protection in the benefit-risk ratio estimation of rotavirus vaccination in children under 5 years of age, in France. *EuroSurveillance* 2020; 25(33):1900538. doi: 10.2807/1560-7917.ES.2020.25.33.1900538.
2. **Mueller JE**. Meningococcal strain evolution, dusty dry air and respiratory tract infections: An explosive relationship. *EBioMedicine*. 2019;42:34-35. doi: 10.1016/j.ebiom.2019.03.067.
3. **Mueller JE**. Long-term effectiveness of MenAfriVac. *Lancet Infect Dis*. 2019;19(3):228-229. doi: 10.1016/S1473-3099(18)30725-4.
4. Koutangni T, Crépey P, Woringer M, Porgo S, Bicaba BW, Tall H, **Mueller JE**. Compartmental models for seasonal hyperendemic bacterial meningitis in the African meningitis belt. *Epidemiol Infect*. 2018. doi: 10.1017/S0950268818002625.
5. Woringer M, Martiny N, Porgo S, Bicaba BW, Bar-Hen A, **Mueller JE**. Atmospheric dust, early cases and localized meningitis epidemics in the African meningitis belt: an analysis using high spatial resolution data. *Envir Health Perspect*, 2018;126:97002. doi: 10.1289/EHP2752..
6. Yaro S, Njanpop Lafourcade BM, Ouangraoua S, Ouoba A, Kpoda H, Findlow H, Tall H, Seanehia J, Martin C, Ouedraogo JB, Gessner B, Meda N, Borrow R, Trotter C, **Mueller JE**. Antibody persistence at the population level 5 years after mass vaccination with meningococcal serogroup A conjugate vaccine (PsA-TT) in Burkina Faso: Need for a booster campaign? *Clin Infect Dis*. 2018 doi: 10.1093/cid/ciy488.
7. Norheim G, **Mueller JE**, Njanpop-Lafourcade BM, Delrieu I, Findlow H, Borrow R, Xie O, Nagaputra J, Ramasamy R, Dold C, Tamekloe TA, Rollier CS, Watt H, Kere AB, Næss LM, Pollard AJ. Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007. *Vaccine*. 2018 pii: S0264-410X(18)30066-5. doi: 10.1016/j.vaccine.2018.01.031.
8. **Mueller JE**, Woringer M, Porgo S, Madec Y, Tall H, Martiny N, Bicaba BW. The association between respiratory tract infection incidence and localised meningitis epidemics: an analysis of high-resolution surveillance data from Burkina Faso. *Scientific Reports*. 2017; 7:11570. doi:10.1038/s41598-017-11889-4
9. Seanehia J, Treibich C, Holmberg C, Müller-Nordhorn J, Casin V, Raude J, **Mueller JE**. Quantifying population preferences around vaccination against severe but rare diseases: A conjoint analysis among French university students, 2016. *Vaccine*. 2017 Apr 10. pii: S0264-410X(17)30438-3. doi: 10.1016/j.vaccine.2017.03.086.
10. Pivette M, Auvigne V, Guérin P, **Mueller JE**. Suivi en quasi-temps réel de la vaccination contre la grippe chez les 65 ans et plus en France à partir des ventes de vaccins en pharmacie. *Rev Epidemiol Santé Publique*. 2017 Feb 9. pii: S0398-7620(17)30001-9. <http://dx.doi.org/10.1016/j.respe.2016.12.025>
11. Blake A, Njanpop-Lafourcade BM, Telles JN, Rajoharison A, Makawa MS, Agbenoko K, Tamekloe S, **Mueller JE**, Tall H, Gessner BD, Paranhos-Baccalà G, Moïsi JC. Evaluation of chest radiography, *lytA* real-time PCR, and other routine tests for diagnosis of community-acquired pneumonia and estimation of possible attributable fraction of pneumococcus in northern Togo. *Epidemiol Infect*. 2017 Feb;145(3):583-594. doi: 10.1017/S0950268816002211.
12. Moïsi JC, Makawa MS, Tall H, Agbenoko K, Njanpop-Lafourcade BM, Tamekloe S, Amidou M, **Mueller JE**, Gessner BD. Burden of pneumococcal disease in northern Togo before the introduction of pneumococcal conjugate vaccine. *PLoS One*. 2017 Jan 23;12(1):e0170412. doi: 10.1371/journal.pone.0170412.
13. Agier L, Martiny N, Thiongane O, **Mueller JE**, Paireau J, Watkins ER, Irving TJ, Koutangni T, Broutin H. Towards understanding the epidemiology of *Neisseria meningitidis* in the African meningitis belt: a multi-disciplinary overview. *Int J Infect Dis*. 2017 Jan;54:103-112. doi: 10.1016/j.ijid.2016.10.032.
14. Maïnassara HB, Oumarou GI, Issaka B, Sidiki A, Idi I, Pelat JM, Fontanet A, **Mueller JE**. Evaluation of response strategies against epidemics due to *Neisseria meningitidis* C in Niger. *Trop Med Int Health*. 2017 Feb;22(2):196-204. doi: 10.1111/tmi.12815.
15. Maïnassara HB, Paireau J, Idi I, Jusot JF, Moulia Pelat JP, Ouwe Missi Oukem-Boyer O, Fontanet A, **Mueller JE**. Serogroup-specific characteristics of localized meningococcal meningitis epidemics in Niger 2002-2012 and 2015: analysis of health center level surveillance data. *PLoS One*. 2016 Sep 22;11(9):e0163110. doi:10.1371/journal.pone.0163110.
16. Tall H, Yaro S, Kpoda HBN, Ouangraoua S, Trotter CL, Njanpop Lafourcade BM, Findlow H, Bai X,

- Martin C, Nwakamma I, Ouedraogo JB, Gessner BD, Borrow R, **Mueller JE**. Meningococcal seroepidemiology in Burkina Faso, one year after a mass immunization campaign with meningococcal serogroup A conjugate vaccine. *Clin Infect Dis* 2015; 61 Suppl 5:S540-6. 9
17. Maïnassara HB, Paireau J, Idi I, Pelat JM, Oukem-Boyer OO, Fontanet A, **Mueller JE**. Response strategies against meningitis epidemics after elimination of serogroup A meningococci, Niger. *Emerg Infect Dis*. 2015; 21:1322-9. 7
 18. Blumental S, Moïsi J, Roalfe L, Zancolli M, Johnson M, Burbidge P, Borrow R, Yaro S, **Mueller JE**, Gessner BD, Goldblatt D. S. pneumoniae serotype 1 burden in the African meningitis belt: is there a lack of functionality in specific antibodies? *Clin Vaccine Immunol*. 2015; 22:404-12. 3
 19. Koutangni T, Maïnassara HB, **Mueller JE**. Incidence, carriage and case-carrier ratios for meningococcal meningitis in the African meningitis belt: a systematic review and meta-analysis. *PLoS ONE* 2015; 10(2):e0116725
 20. **Mueller JE**, Kitar S, Bloch MA. Le Réseau doctoral en santé publique. *Cahiers de fonction publique* 2014; 348:70-3.
 21. Pivette M, **Mueller JE**, Crépey P, Bar-Hen A. Drug sales data analysis for outbreak detection of infectious diseases: a systematic literature review. *BMC Infect Dis* 2014; 14:604.
 22. Paireau J, Maïnassara HB, Jusot JF, Collard JM, Idi I, Moulija-Pelat JP, **Mueller JE**, Fontanet A. Spatio-temporal factors associated with meningococcal meningitis annual incidence at the health centre level in Niger, 2004–2010. *PLoS Negl Trop Dis* 2014; 8:e2899.
 23. Pivette M, **Mueller JE**, Crépey P, Bar-Hen A. Surveillance of gastrointestinal disease in France using drug sales data. *Epidemics* 2014; 8:1-8.
 24. Comboroure JC, **Mueller JE**. Perception de la vaccination et rôle du pharmacien d'officine: une enquête auprès des étudiants en dernière année de pharmacie en France. [Perception of vaccination and role of the pharmacist: a survey among final year pharmacy students in France.] *Ann Pharm Fr* 2014; 72:122-31.
 25. Banke-Thomas AO, Kouraogo SF, Siribie A, Taddese HB, **Mueller JE**. Knowledge of obstetric fistula prevention amongst young women in urban and rural Burkina Faso: a cross-sectional study. *PLoS ONE* 2013; 8:e85921.
 26. Yaro S, Njanpop-Lafourcade BM, Drabo A, Idohou RI, Kroman SS, Sanou O, Traoré Y, Sangaré L, Diabougoua SP, Koeck JL, Borrow R, Gessner BD, **Mueller JE**. Anti-pneumococcal seroprevalence and pneumococcal carriage during a meningococcal epidemic in Burkina Faso, 2006. *J Infect Dis* 2014; 209:1241-50.
 27. Xie O, Pollard AJ, **Mueller JE**, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. *Vaccine* 2013; 31 2852-61.
 28. Trotter CL, Yaro S, Njanpop-Lafourcade BM, Drabo A, Kroman SS, Idohou RS, Sanou O, Bowen L, Findlow H, Diabougoua S, Gessner BD, Borrow R, **Mueller JE**. Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A *Neisseria meningitidis* by age in Burkina Faso 2008. *PLoS ONE* 2013. 8:e55486.
 29. Dakar discussion group on priorities for research on epidemic meningococcal disease in Africa, Altmann D, Aseffa A, Bash M, Basta N, Borrow R, Broome C, Caugant D, Clark T, Collard JM, Djingarey M, Goldblatt D, Greenwood B, Griffiths U, Hajjeh R, Hassan-King M, Hugonnet S, Kimball AM, LaForce M, MacLennan C, Maiden MC, Manigart O, Mayer L, Messonnier N, Moisi J, Moore K, Moto DD, **Mueller J**, et al. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. *Vaccine* 2013; 31:1453-7.
 30. **Mueller JE**. Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives. *Trop Med Internat Health* 2013; 18:58-64.
 31. **Mueller JE**. Yaro S, Ouédraogo MS, Levina N, Njanpop-Lafourcade BM, Tall H, Idohou RS, Sanou O, Kroman SS, Drabo A, Nacro B, Millogo A, van der Linden M, Gessner BD. Pneumococci in the African meningitis belt: meningitis incidence and carriage prevalence in children and adults. *PLoS ONE* 2012; 7:e52464
 32. Tall H, Hugonnet S, Donnen P, Dramaix-Wilmet M, Kambou L, Drabo F, **Mueller JE**. Definition and characterization of localized meningitis epidemics in Burkina Faso. *BMC Infect Dis* 2012; e12:2.
 33. **Mueller JE**, Yaro S, Njanpop-Lafourcade BM, Drabo A, Idohou RS, Kroman SS, Sanou O, Diabougoua S, Traoré Y, Sangaré L, Borrow R, Gessner BD. Study of a localized meningococcal

- meningitis epidemic in Burkina Faso: incidence, carriage and immunity. *J Infect Dis* 2011; 204:1787-95.
34. Delrieu I, Yaro S, Tamekloé TAS, Njanpop-Lafourcade BM, Tall H, Jaillard P, Ouedraogo MS, Badziklou K, Sanou O, Drabo A, Gessner BD, Kambou JL, **Mueller JE**. Emergence of epidemic *Neisseria meningitidis* serogroup X meningitis in Togo and Burkina Faso. *PLoS ONE* 2011; 6:e19513.
 35. **Mueller JE**, Gessner BD. A hypothetical model for meningococcal meningitis in the African meningitis belt. *Int J Infect Dis* 2010; 15:e553-9.
 36. Gessner BD, **Mueller JE**, Yaro S. African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults. *BMC Infect Dis* 2010; 10:22.
 37. Njanpop Lafourcade BM, Sanou O, van der Linden M, Levina N, Karanfil M, Yaro S, Tamekloe TA, **Mueller JE**. Serotyping pneumococcal meningitis cases in the African meningitis belt using multiplex PCR on cerebrospinal fluid. *J Clin Microbiol* 2010; 48:612-4.
 38. **Mueller JE**, Bessaud M, Huang QS, Martinez LC, Barril PA, Morel V, Balanant J, Bocacao J, Hewitt J, Gessner BD, Delpeyroux F, Nates SV. Environmental poliovirus surveillance during OPV and IPV use in Córdoba Province, Argentina. *Appl Environ Microbiol* 2009; 75:1395-401.
 39. **Mueller JE**, Yaro S, Madec Y, Somda PK, Idohou RS, Njanpop Lafourcade BM, Drabo A, Tarnagda Z, Sangaré L, Traoré Y, Fontanet A, Gessner BD. Association of respiratory tract infection symptoms and air humidity with meningococcal carriage in Burkina Faso. *Trop Med Int Health* 2008; 13:1543-52.
 40. **Mueller JE**, Sangaré L, Njanpop-Lafourcade BM, Tarnagda Z, Traoré Y, Yaro S, Borrow R, Gessner BD, Nicolas P. Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003. *Emerging Infect Dis* 2007; 13:847-54.
 41. **Mueller JE**, Borrow R, Gessner BD. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines. *Expert Rev Vaccines* 2006; 5(3).
 42. **Mueller JE**, Yaro S, Traoré Y, Sangaré L, Tarnagda Z, Njanpop-Lafourcade BM, Borrow R, Gessner BD. *Neisseria meningitidis* serogroup W135 and A: carriage and immunity in Burkina Faso, 2003. *J Infect Dis* 2006; 193:812-20.
 43. **Mueller JE**, Frye C, Brasche S, Heinrich J. Association of hormone replacement therapy with bronchial hyper-responsiveness. *Respiratory Med* 2003; 97:990-2.
 44. **Mueller JE**, Döring A, Heier M, Löwel H. Prevalence and determinants of hormone replacement therapy in German women 1984-1995. *Maturitas* 2002; 43:95-104.
 45. Barrett-Connor E, **Mueller JE**, von Mühlen DG, Laughlin GA, Schneider DL, Sartoris DJ. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. *J Clin Endocrinol Metab* 2000; 85:219-223.